<p>Representative fluorescence-activated cell sorting (FACS) plots are shown in the upper panels with BrdU positive cells (purple) shown within the upper gate. The mean percentage (± SD) of HT1080 and HCT116 BrdU positive cells after treatment with DMSO (white bar), TM5275 (black bar) or TM5441 (red bar) was graphed, n = 3. * indicates <i>P</i> values compared to DMSO controls < 0.05, ** indicates <i>P</i> < 0.01, and *** indicates <i>P</i> < 0.001.</p
<p>The proliferation of HN12 cells adherent to matrix proteins following treatment with vehicle DMSO...
<p>(A) BrdU immunocytochemistry assay. Left column: control group (CTR), centre: “starved” group (ST...
After 24- or 48-hour treatments with 0.1% DMSO (vehicle control) or with M344 at 5 or 10 μM concentr...
<p><b>A</b>. Caspase 3/7 activity of HT1080 and HCT116 cells treated with increasing concentrations ...
After treatment with M344 at various concentrations, the proliferation of (A) S2-013, (B) BxPC-3, (C...
<p><b>A.</b> The structures and chemical names of TM5275 and TM5441 are shown. <b>B.</b> The indicat...
<p>(<b>A</b>) Colony formation assay of H1299 p53β, H1299 p53γ and H1299 vector control demonstrated...
<p>(<b>A</b>–<b>C</b>) Human A549 and H1299 cells were treated with BBR at the indicated doses. At 4...
<p>Cells were seeded in 96-well plates in 0.2 ml of media as described below for 72 hours, followed ...
<p>The S-phase proliferating cells of WT, <i>fgfr2c</i>, and <i>fgfr2c-5 </i><i>mm</i> morphants wer...
<p>Proliferation of HM3KO cells treated with a solvent (0.1% of DMSO) (open circle in A, lane 1 in B...
<p>(A) Control and hUCBSC-treated glioma cells at different time points were analyzed for cell proli...
<p>(A) BrdU incorporation after 4 days of TCR stimulation with the indicated treatments. Results are...
<p><b>A</b>. Representative immunoblots for HT1080 and HCT116 cells treated with 25 μM or 50 μM TM52...
<p><b>A.</b> PI/FACS analysis of HF cell cycle progression after DMSO and bDHC treatments for 24 and...
<p>The proliferation of HN12 cells adherent to matrix proteins following treatment with vehicle DMSO...
<p>(A) BrdU immunocytochemistry assay. Left column: control group (CTR), centre: “starved” group (ST...
After 24- or 48-hour treatments with 0.1% DMSO (vehicle control) or with M344 at 5 or 10 μM concentr...
<p><b>A</b>. Caspase 3/7 activity of HT1080 and HCT116 cells treated with increasing concentrations ...
After treatment with M344 at various concentrations, the proliferation of (A) S2-013, (B) BxPC-3, (C...
<p><b>A.</b> The structures and chemical names of TM5275 and TM5441 are shown. <b>B.</b> The indicat...
<p>(<b>A</b>) Colony formation assay of H1299 p53β, H1299 p53γ and H1299 vector control demonstrated...
<p>(<b>A</b>–<b>C</b>) Human A549 and H1299 cells were treated with BBR at the indicated doses. At 4...
<p>Cells were seeded in 96-well plates in 0.2 ml of media as described below for 72 hours, followed ...
<p>The S-phase proliferating cells of WT, <i>fgfr2c</i>, and <i>fgfr2c-5 </i><i>mm</i> morphants wer...
<p>Proliferation of HM3KO cells treated with a solvent (0.1% of DMSO) (open circle in A, lane 1 in B...
<p>(A) Control and hUCBSC-treated glioma cells at different time points were analyzed for cell proli...
<p>(A) BrdU incorporation after 4 days of TCR stimulation with the indicated treatments. Results are...
<p><b>A</b>. Representative immunoblots for HT1080 and HCT116 cells treated with 25 μM or 50 μM TM52...
<p><b>A.</b> PI/FACS analysis of HF cell cycle progression after DMSO and bDHC treatments for 24 and...
<p>The proliferation of HN12 cells adherent to matrix proteins following treatment with vehicle DMSO...
<p>(A) BrdU immunocytochemistry assay. Left column: control group (CTR), centre: “starved” group (ST...
After 24- or 48-hour treatments with 0.1% DMSO (vehicle control) or with M344 at 5 or 10 μM concentr...